Protein S deficiency represents a rare but significant hereditary thrombophilia that poses substantial risks during pregnancy ...
Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study. This is an ASCO Meeting ...
Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.
Objectives Studies on ageing trajectories typically foreground intrinsic capacities and focus on frailty and mortality outcomes. Instead, research capturing aspects of people’s living environment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results